Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2020-11-09
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Microalgae as an Alternative Protein Source in Human Nutrition.
NCT05401591
The Bioavailability of Multiple Novel, Sustainable, Non-animal Derived Protein Sources
NCT04297137
The Effect of Ingesting a Novel Algae Protein Source on Rested and Exercised Muscle Protein Synthesis Rates in Older Adults.
NCT06852547
Bioavailability of Plant Protein Amino Acids
NCT04872530
Bioavailability of Legume Proteins in Differents Products
NCT06624033
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A sup-group of five participants per group consume a test meal after the fasting blood sampling on the first study day. This is followed by a postprandial blood sampling after 30, 60, 90, 120 and 180 minutes.
The NovAL study is conducted to evaluate the bioavailability of nutrients such as omega-3 LC-PUFA, vitamin D, vitamin B12, further vitamins, amino acids, minerals, and trace elements from the selected microalgae species. Therefore, the concentration of these valuable nutrients and relevant markers of their status in humans (e.g. vitamin B12 status: holo-transcobalamin, methylmalonic acid, homocysteine; iron status: ferritin, transferrin, transferrin saturation) are analysed in the human biofluids (serum/plasma, erythrocytes, 24 h urine) before and after defined consumption of the selected microalgae species over 14 days. Besides the comprehensive analysis of the nutrient status in humans, cardiovascular risk factors and risk factors for diabetes mellitus type II are analysed. Thus, the NovAL study allows the assessment of i) the nutrient bioavailability from the selected microalgae species but also ii) their contribution on nutrient supply and prevention of non-communicable diseases such as cardiovascular diseases or diabetes mellitus type.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Microalgae I
Smoothie (enriched with Chlorella pyrenoidosa) and standardised background diet (defined menu plans)
Smoothie with microalgae
Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
Microalgae II
Smoothie (enriched with Nannochloropsis salina) and standardised background diet (defined menu plans)
Smoothie with microalgae
Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
Smoothie
Smoothie (without microalgae) and standardised background diet (defined menu plans)
Smoothie with microalgae
Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
Control
no intervention (no smoothie, no menu plans)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Smoothie with microalgae
Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \< 30 kg/m2
* subjects must be able and willing to give written informed consent, and to comply with study procedures
* participants following a traditional Western diet composed of dairy products, sausage, meat, fast foods, chocolate and snacks, cereals, vegetables, and fruits (PAL: 1.6)
* precondition: Stable eating habits of at least one years before enrolment
* subjects must have adequate fluency in the German language to complete the questionnaires and understand the nutritional recommendations
Exclusion Criteria
* use of prescription medicine which could affect results of the study, including systemic glucocorticoids
* intake of lipid-lowering drugs, diabetes medication, hormone replacement therapy
* estimated glomerular filtration (eGFR) rate \< 60 ml/min
* weight loss (≤ 3 kg) or weight gain (≥ 3 kg) during the last three months before study begin
* pregnancy or lactation
* transfusion of blood in the last three months before blood sample taking
* use of dietary supplements incl. multivitamins, fish oil capsules, minerals, and trace elements (three months before and during the entire study period)
* vegetarians, vegans, food allergies
* dependency on alcohol or drugs
* elite athletes (\>10 hours of strenuous physical activity per week)
* simultaneous participation in other clinical studies
* inability (physically or psychologically) to comply with the procedures required by the protocol
20 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Federal Ministry of Education and Research
OTHER_GOV
University of Jena
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christine Dawczynski,PhD
Study leader
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Friedrich Schiller University
Jena, Thuringia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H10_20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.